Group A and C Meningococcal Conjugate Vaccine (GACCV) is a vaccine for the prevention of epidemic cerebrospinal meningitis (ECM). Group A and C Meningococcal Conjugate Vaccine (GACV) can produce humoral immune response after vaccination, and is used to prevent meningococcal infections of groups A and C. It is suitable for children over 6 months of age or adults, and belongs to the second category of vaccines, which need to be paid for by themselves. Group A and C meningococcal conjugate vaccine is safe and has fewer adverse reactions after vaccination, mainly fever, abdominal symptoms, nausea, vomiting, etc. The symptoms are mild and can be relieved on their own. If serious discomfort occurs after vaccination, one should consult a doctor promptly. Epidemic cerebrospinal meningitis is an acute suppurative meningitis caused by Neisseria meningitidis infection, which can be spread through respiratory droplets, and the main symptoms of infection are fever, headache, vomiting, etc., which can lead to respiratory distress and shock in severe cases. Early vaccination against N. meningitidis can effectively prevent the infection, therefore, timely vaccination against N. meningitidis is very necessary.